View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 20, 2021

FDA panel favours Pfizer-BioNTech’s Covid-19 booster shot for elderly

The committee also recommends granting EUA to the booster for use in some people at higher risk of severe Covid-19. 

The US Food and Drug Administration’s (FDA) advisory committee has voted unanimously in favour of granting emergency use authorization (EUA) to Pfizer and BioNTech’s booster dose of Covid-19 vaccine, Comirnaty, in people aged 65 years and above.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) also recommended EUA for the booster shot in certain individuals at increased risk of severe Covid-19.

third dose of the messenger ribonucleic acid (mRNA) vaccine obtained FDA EUA for use in some immunocompromised people aged a minimum of 12 years.

According to the EUA, the vaccine is indicated for solid organ transplant recipients or those with conditions on an equivalent immunocompromise level.

The panel advised using a third dose of the vaccine after a minimum of six months following the two-dose regimen.

Furthermore, the committee noted that healthcare staff and other individuals at increased risk for occupational exposure should be part of this EUA.

VRBPAC comprises independent specialists who recommend scientific and regulatory matters, including the assessment of vaccine safety and efficacy, to the FDA.

The panel did not vote in favour of approval of booster shots for people aged 16 or above for which the companies submitted their supplemental Biologics License Application.

An FDA decision on the approval is anticipated soon, Pfizer noted adding that it would make Comirnaty the first Covid-19 vaccine with a booster shot authorised in the US.

Pfizer Vaccine Research and Development senior vice-president and head Kathrin Jansen said: “Today, the VRBPAC reviewed data from our clinical programme showing a favourable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine.

“These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus.”

The VRBPAC recommendation was based on the totality of scientific data shared by Pfizer and BioNTech, including results from clinical programmes assessing the safety, tolerability and immunogenicity of the booster.

A booster shot induced substantially higher neutralising antibody titers against the wild type SARS-CoV-2 virus and Beta and Delta variants, as against levels reported after the two-dose regimen.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology